A
Adelaide Eye and Retina Centre | Adelaide, South Australia
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
KHK4951
BI 765128
Lampalizumab
Dexamethasone
EXN407
Aflibercept
JNJ-81201887
IBE-814
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
4 of 11 total trials
The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure
Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...
Enrolling
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
Enrolling
Diabetic Macular Edema (DME)
Drug: KHK4951
Drug: Aflibercept Injection
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Aflibercept Injection
Drug: KHK4951
Trial sponsors
E
R
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems